RESUMEN
The introduction of innovative therapies has changed the scenario of complications. The delay in the recognition of kidney adverse effects is partly due to the timing of the development of the kidney damage which occurs later than the observation period of registration studies, and partly to the exclusion of patients with known kidney impairment from registration trials. Renal disease has a significant impact on the management of cancer patients and often leads to discontinuation of therapy. Histological evaluations of kidney disorders induced by targeted/immunotherapy are very limited. Renal biopsy is critical for the management of renal toxicities and should be especially encouraged for patients showing adverse renal effects to novel cancer agents. We recently examined the histological features of patients treated with new cancer agents who underwent renal biopsy for new onset renal failure and/or urinary abnormalities. The cohort included 42 patients. The most frequently administered therapies were immunotherapy (54.8%) and anti-angiogenic treatments (45.2%). The most common adverse effect was tubular interstitial nephritis in the first group and thrombotic microangiopathy in the second one. Based on histological findings, definitive discontinuation of treatment could be restricted to a very limited number of patients. All of them had anti-VEGF-related TMA. Treatment discontinuation was unneeded in patients treated with ICIs. In patients treated with multidrug therapy, the histological findings made it possible to identify the weight of drug-related specific injury. Based on this data, renal biopsy should be considered in every cancer patient who develops urinary abnormalities or shows a worsening of renal function during treatment with immunotherapy or targeted therapy.
Asunto(s)
Antineoplásicos , Enfermedades Renales , Neoplasias , Humanos , Quimioterapia Combinada , Terapia Molecular Dirigida/efectos adversos , Leprostáticos/efectos adversos , Riñón/patología , Antineoplásicos/efectos adversos , Enfermedades Renales/tratamiento farmacológico , Neoplasias/tratamiento farmacológicoAsunto(s)
Adenocarcinoma del Pulmón/tratamiento farmacológico , Antineoplásicos/efectos adversos , Enfermedades del Colágeno/inducido químicamente , Clorhidrato de Erlotinib/efectos adversos , Neoplasias Pulmonares/tratamiento farmacológico , Enfermedades de la Piel/inducido químicamente , Enfermedades del Colágeno/diagnóstico , Enfermedades del Colágeno/terapia , Femenino , Humanos , Persona de Mediana Edad , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/terapiaAsunto(s)
Antineoplásicos/efectos adversos , Mesilato de Imatinib/efectos adversos , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Piodermia Gangrenosa/inducido químicamente , Piodermia Gangrenosa/patología , Femenino , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Persona de Mediana EdadAsunto(s)
Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/tratamiento farmacológico , Dermatosis Facial/inducido químicamente , Síndrome Mano-Pie/etiología , Neoplasias Hepáticas/tratamiento farmacológico , Sorafenib/efectos adversos , Resultado Fatal , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Granuloma Piogénico/inducido químicamente , Granuloma Piogénico/diagnóstico , Hemangioma/inducido químicamente , Hemangioma/diagnóstico , Paclitaxel/efectos adversos , Adulto , Antineoplásicos/efectos adversos , Humanos , Masculino , Neoplasias Primarias Secundarias/inducido químicamente , Neoplasias Primarias Secundarias/diagnóstico , RamucirumabAsunto(s)
Antineoplásicos/efectos adversos , Mesilato de Imatinib/efectos adversos , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Porfirias/inducido químicamente , Anciano , Femenino , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/diagnóstico , Porfirias/diagnósticoAsunto(s)
Erupciones Acneiformes/inducido químicamente , Antineoplásicos/efectos adversos , Erupciones por Medicamentos/etiología , Hiperpigmentación/inducido químicamente , Enfermedades de la Uña/inducido químicamente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Femenino , Enfermedades del Cabello/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de la Boca/inducido químicamenteRESUMEN
BACKGROUND: Previous reports regarding the cutaneous adverse events of epidermal growth factor receptor inhibitors are mostly limited to small case reports and case series, mainly involving Caucasian patients. AIMS: We describe the trends in the clinical presentation of Asian patients who had cutaneous adverse events induced by epidermal growth factor receptor inhibitors and to explore the relationship between skin adverse events and tumor response. METHODS: From 2006 to 2010, medical records of Thai patients with non-small cell lung cancer receiving epidermal growth factor receptor inhibitors were retrieved and analyzed. RESULTS: In all, 99 patients were reviewed and analyzed. Erlotinib and gefitinib were commenced in 75 (75.8%) and 24 (24.2%) patients, respectively. Cutaneous adverse events occurred in 43 (57.3%) patients receiving erlotinib and in 15 (62.5%) patients receiving gefitinib. The most common adverse event was xerosis (52.5%). Less common adverse events included papulo-pustular eruption (27.3%), erythematous maculopapular rash (11.1%), mucositis (6.7%), paronychia (5.1%), and trichomegaly (2%). Elderly patients had a higher occurrence of xerosis. The presence of cutaneous adverse events was significantly higher in subjects who had a tumor response. LIMITATIONS: The limitations of study include its retrospective nature, and the initial screening of cutaneous adverse events was done by non-dermatologists. CONCLUSIONS: Cutaneous adverse events due to epidermal growth factor receptor inhibitors are not uncommon in the Asian population. We found a positive correlation between the occurrences of cutaneou adverse events and tumor response supporting the view that they are surrogate markers for therapeutic response.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Receptores ErbB/antagonistas & inhibidores , Clorhidrato de Erlotinib/efectos adversos , Neoplasias Pulmonares/tratamiento farmacológico , Quinazolinas/efectos adversos , Enfermedades Cutáneas Papuloescamosas/inducido químicamente , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Erupciones por Medicamentos/diagnóstico , Clorhidrato de Erlotinib/uso terapéutico , Femenino , Estudios de Seguimiento , Gefitinib , Humanos , Neoplasias Pulmonares/metabolismo , Masculino , Persona de Mediana Edad , Quinazolinas/uso terapéutico , Estudios Retrospectivos , Enfermedades Cutáneas Papuloescamosas/diagnósticoAsunto(s)
Antineoplásicos/efectos adversos , Erupciones por Medicamentos/etiología , Hiperpigmentación/inducido químicamente , Taxoides/efectos adversos , Administración Intravenosa , Anciano , Antineoplásicos/administración & dosificación , Neoplasias de la Mama Masculina/tratamiento farmacológico , Carcinoma Ductal de Mama/tratamiento farmacológico , Docetaxel , Humanos , Masculino , Taxoides/administración & dosificaciónAsunto(s)
Aminoquinolinas/efectos adversos , Antineoplásicos/efectos adversos , Linfoma de Células B de la Zona Marginal/inducido químicamente , Linfoma de Células B de la Zona Marginal/diagnóstico , Administración Tópica , Anciano de 80 o más Años , Aminoquinolinas/administración & dosificación , Antineoplásicos/administración & dosificación , Humanos , Imiquimod , MasculinoAsunto(s)
Bortezomib/efectos adversos , Histiocitos/patología , Mieloma Múltiple/diagnóstico , Síndrome de Sweet/diagnóstico , Anciano , Antineoplásicos/efectos adversos , Diagnóstico Diferencial , Humanos , Masculino , Mieloma Múltiple/tratamiento farmacológico , Síndrome de Sweet/inducido químicamenteRESUMEN
Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We report a case of Stevens Johnson syndrome-toxic epidermal necrolysis developing in an elderly male who was prescribed thalidomide after being diagnosed with multiple myeloma.
Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Mieloma Múltiple/tratamiento farmacológico , Síndrome de Stevens-Johnson/etnología , Talidomida/efectos adversos , Anciano , Inhibidores de la Angiogénesis/administración & dosificación , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Humanos , Masculino , Talidomida/administración & dosificaciónRESUMEN
Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma. New thalidomide analogues have been developed but lack clinical experience. This paper is a review of the history, pharmacology, mechanism of action, clinical applications and side effects of thalidomide and its analogues.